Clinicopathological study of neuro-glial damage biomarkers in central nervous system diseases

Clinicopathological study of neuro-glial damage biomarkers in central nervous system diseases - Biomarker study of the CNS diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006221

Enrollment

150

Registered

2011-09-01

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis and allied disorders

Interventions

To test a serum and cerebrospinal fluid level of glial and other biomarkers, and to observe the diagnotic or prognostic value of the diseases

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with multiple sclerosis and alliged disorders, who had received lumbar puncture for the diagnosis and agreed to the informed consent.

Exclusion criteria

Exclusion criteria: Patients who will not agree to the study design.

Design outcomes

Primary

Measure	Time frame
This study will bring us the promising tool in making dianogosis or therapeutic strategy in demyelinating diseases including multiple sclerosis and neuromyelitis optica	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026